Evommune (EVMN) Other Accumulated Expenses (2024 - 2026)

Evommune's (EVMN) quarterly Other Accumulated Expenses came in at $571000.0 in Q1 2026, down 9.65% on a QoQ basis from $632000.0 in Q4 2025.

Evommune (EVMN) Other Accumulated Expenses (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Other Accumulated Expenses data on file, last reported at $571000.0 in Q1 2026.

On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $571000.0 in Q1 2026; TTM through Mar 2026 was $571000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $632000.0, up 10.3% from the prior year.
Other Accumulated Expenses for Q1 2026 stood at $571000.0, down from $632000.0 in the prior quarter.
Over the last five years, Other Accumulated Expenses for EVMN reached as high as $632000.0 in Q4 2025 and fell as low as $449000.0 in Q3 2025.
Historically, Other Accumulated Expenses has averaged $556250.0 across 3 years, with a median of $572000.0 in 2024.
On a YoY basis, Other Accumulated Expenses climbed as much as 10.3% in 2025 and fell as far as 10.3% in 2025.
Year by year, Other Accumulated Expenses stood at $573000.0 in 2024, then grew by 10.3% to $632000.0 in 2025, then fell by 9.65% to $571000.0 in 2026.
Per Business Quant data, the three most recent Other Accumulated Expenses figures were $571000.0 in Q1 2026, $632000.0 in Q4 2025, and $449000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Evommune	381.48 Mn	170.02 Mn	-

Download Data